Figure 1. Flow charts. ICU: intensive care unit.
| Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc |
| Journal website https://www.thejh.org |
Original Article
Volume 9, Number 4, December 2020, pages 109-115
Reduce Mortality and Morbidity in Acute Myeloid Leukemia With Hyperleukocytosis With Early Admission in Intensive Care Unit: A Retrospective Analysis
Figures
Table
| Entire cohort (n = 154, % or IQR) | No ICU (n = 77, % or IQR) | Late ICU (n = 18, % or IQR) | Early ICU (n = 59, % or IQR) | P | |
|---|---|---|---|---|---|
| IQR: interquartile range; PS: performance status; FAB: French-American-British; ICU: intensive care unit; CRP: C-reactive protein; DIC: disseminated intravascular coagulation; i-MV: invasive mechanical ventilation; NIV: non-invasive mechanical ventilation; LST: life-sustaining therapy. | |||||
| Median age | 60 (46 - 69) | 60 (47 - 70) | 59 (53 - 69) | 60 (44 - 67) | 0.56 |
| PS | 1 (1 - 2) | 1 (1 - 2) | 1 (1 - 2) | 1 (1 - 2) | 0.58 |
| Median Charlson comorbidity score | 0 (0 - 1) | 0 (0 - 1) | 0 (0 - 2) | 0 (0 - 1) | 0.87 |
| FAB classification | |||||
| M0 | 6 (4%) | 2 (3%) | 3 (17%) | 1 (2%) | |
| M1 | 27 (18%) | 13 (17%) | 1 (6%) | 13 (22%) | |
| M2 | 21 (14%) | 16 (21%) | 0 (0%) | 5 (9%) | |
| M3 | 2 (1%) | 0 (0%) | 1 (6%) | 1 (2%) | |
| M4 | 45 (29%) | 23 (30%) | 6 (33%) | 16 (27%) | |
| M5 | 39 (25%) | 14 (18%) | 4 (22%) | 21 (36%) | |
| Unknown | 14 (9%) | 9 (12%) | 3 (17%) | 2 (3%) | |
| FAB 4/5 | 84 (54%) | 37 (48%) | 10 (56%) | 37 (63%) | 0.23 |
| CRP (mg/L) | 54 (21 - 121) | 39 (13 - 121) | 74 (41 - 98) | 56 (29 - 130) | 0.23 |
| Median leukocyte at diagnosis | 92 (66 - 149) | 74 (61 - 104) | 68 (56 - 155) | 140 (91 - 197) | < 0.001 |
| Leukocyte at day 1 | 74 (51 - 128) | 60 (39 - 84) | 65 (49 - 148) | 118 (70 - 197) | < 0.001 |
| Leukostasis | 26 (17%) | 5 (6%) | 6 (33%) | 15 (25%) | 0.001 |
| Biological DIC | 29 (19%) | 9 (12%) | 7 (39%) | 13 (22%) | 0.025 |
| Clinical DIC | 5 (3%) | 2 (3%) | 1 (5%) | 2 (3%) | 0.67 |
| Dexamethasone | 60 (39%) | 1 (1.3%) | 0 (0%) | 59 (100%) | < 0.001 |
| Hydroxyurea | 99 (64 %) | 36 (47%) | 4 (22%) | 59 (100%) | < 0.001 |
| i-MV | 8 (44.4%) | 11 (18.6%) | |||
| Renal replacement therapy | 2 (11.1%) | 3 (5.1%) | |||
| Amines | 6 (33.3%) | 7 (11.9%) | |||
| NIV | 3 (17.7%) | 9 (15.3%) | |||
| LST | 10 (56%) | 17 (29%) | |||
| 30-day mortality | 17 (11%) | 2 (2.6%) | 5 (27.8%) | 10 (16.9%) | < 0.001 |
| 7-day mortality | 10 (6.5%) | 1 (1.3%) | 3 (16.7%) | 6 (10.2%) | 0.008 |
| Complete remission | 111 (72%) | 60 (78%) | 11 (61%) | 40 (68%) | 0.23 |